When I lost weight on WW, I devoted all of my time to the program and I was successful. It was when life got hard that the ...

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

The weight loss injection tirzepatide helped Melanie Ressa lose weight and overcome food noise, emotional eating, and mental ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Weight loss and diabetes drugs Ozempic, Wegovy, Mounjaro and Zepbound are seen as game-changers for obesity and weight ...

Data for tirzepatide, the chemical compound Lilly sells as Mounjaro and Zepbound, has separately showed the blockbuster ...